Developing a medicine begins with sifting through an enormous number of possible molecules to find a few worth testing. AI models trained on chemistry and biology data help researchers predict which candidates are most likely to work and least likely to be harmful, narrowing the search before slow laboratory work begins. This use has expanded across research in 2026.
The promise is speed in the earliest, most uncertain stage. It does not shortcut the years of testing and trials needed to prove a drug is safe and effective in people. Scientists treat the models as a way to focus effort, pointing attention at the most promising leads rather than replacing the experiments that follow.